NEW BRUNSWICK, N.J., July 18, 2022 -- Johnson & Johnson (NYSE: JNJ) today announced that Michael (Mike) Ullmann will retire from his position as Executive Vice President, General Counsel at the end of this year, following 33 years of leadership and service to the Company. Throughout his distinguished career, Mr. Ullmann has worked with the organization’s Board of Directors and partnered with four company CEOs to shape and grow Johnson & Johnson into the most broadly based healthcare company in the world.
He will be succeeded in this role by Elizabeth (Liz) Forminard, a strong Credo-based leader who has had an exceptional career with depth and breadth across the Company’s Pharmaceutical, MedTech, and Consumer Health sectors. Ms. Forminard will also be appointed as a member of Johnson & Johnson’s Executive Committee, effective October 17, 2022. Mr. Ullmann and Ms. Forminard will work together during a transition period until Mr. Ullmann’s retirement at the end of this year.
“For three decades, Mike set the standard for Credo leadership at the Company. I thank him for his unwavering commitment to help deliver on Our Purpose of advancing health for humanity,” said Joaquin Duato, Chief Executive Officer, Johnson & Johnson. “Throughout his tenure, Mike has guided the company through an evolving global environment with respect and clarity, always keeping our patients and customers at the center of all decisions.”
Mr. Ullmann joined Johnson & Johnson as a mergers & acquisitions attorney in 1989 and has since held positions of increasing responsibility in the Company’s Law Department, ultimately serving as General Counsel for the past 11 years. During this time, Mr. Ullmann has led the Company through complex matters while ensuring all Company standards and policies reflect the needs of a changing world and a new generation of employees, underscoring a commitment to diversity, equity and inclusion (DEI) and reinforcing the Company’s dedication to the health of humanity. A dedicated advocate for DEI, he has also served as the executive sponsor for the Company’s Hispanic and Latino employee resource group and as a member of the Leadership Council on Legal Diversity, an organization that works to build a more open and diverse legal profession.
Liz Forminard has been with Johnson & Johnson for 16 years, having served as General Counsel across each of the Pharmaceutical, Consumer Health and MedTech sectors, as well as Worldwide Vice President leading the Corporate Governance function, and numerous other functional and business-facing roles during this time. Throughout her tenure on the Law Department Executive Committee (LDEC), Ms. Forminard has built and led global teams who share her passion for the role legal can play in driving innovation and influencing the external environment to enable positive patient outcomes. In her most recent role, Ms. Forminard served as General Counsel for the Pharmaceuticals Legal Group and member of the Pharmaceuticals Group Operating Committee, leading the legal function globally for the sector and for Johnson & Johnson Global External Innovation and Global Public Health, where she drove programs to ensure optimal, aligned intellectual property, regulatory and commercial strategies internally, and helped to shape the global healthcare environment externally.
“I’m thrilled to appoint Liz to this important role and will lean on her strong business acumen and understanding of patient and customer needs during this pivotal time at our Company,” said Mr. Duato. “I’m confident her distinguished experience and leadership will help us find new pathways to bring innovative healthcare solutions to those in need all over the world.”
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Cautions Concerning Forward Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. A list and descriptions of risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the Company's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.